RNA binding Motif protein-38 regulates myocardial hypertrophy in LXR-α-dependent lipogenesis pathway

References

• Han D, Gao Q, Cao F. Long non-coding RNAs (LncRNAs) - The dawning of a new treatment for cardiac hypertrophy and heart failure. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2078–2084.
   PubMed Web of Science ®Google Scholar
• Chothani S, Schäfer S, Adami E, et al. Widespread translational control of fibrosis in the human heart by RNA-Binding proteins. Circulation. 2019;140(11):937–951.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chang Y, Zhang N, et al. Atorvastatin attenuates myocardial hypertrophy in spontaneously hypertensive rats via the C/EBPβ/PGC-1α/UCP3 pathway. Cell Physiol Biochem. 2018;46(3):1009–1018.
   PubMedGoogle Scholar
• Tang L, Xie J, Yu X, et al. MiR-26a-5p inhibits GSK3β expression and promotes cardiac hypertrophy in vitro. PeerJ. 2020;8:e10371.
   PubMed Web of Science ®Google Scholar
• Heinzel FR, Hohendanner F, Jin G, et al. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. Journal of applied physiology (Bethesda, Md.: 1985). 2015;119(10):1233–1242.
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191–227.
   PubMed Web of Science ®Google Scholar
• Ladd AN. New insights into the role of RNA-Binding proteins in the regulation of heart development. Int Rev Cell Mol Biol. 2016;324:125–185.
   PubMed Web of Science ®Google Scholar
• Felicetta A, Condorelli G. RNA binding protein and microRNA control of endothelial cell function. Cardiovasc Res. 2019;115(12):1690–1691.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang M, Qian Y, et al. Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability. J Biol Chem. 2014;289(6):3164–3175.
   PubMed Web of Science ®Google Scholar
• Heinicke LA, Nabet B, Shen S, et al. The RNA binding protein RBM38 (RNPC1) regulates splicing during late erythroid differentiation. PLoS One. 2013;8(10):e78031.
   PubMed Web of Science ®Google Scholar
• Sonnenschein K, Fiedler J, Pfanne A, et al. Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury. Cardiovasc Res. 2019;115(12):1804–1810.
   PubMed Web of Science ®Google Scholar
• van den Hoogenhof MMG, van der Made I, Beqqali A, et al. The RNA-binding protein Rbm38 is dispensable during pressure overload-induced cardiac remodeling in mice. PloS One. 2017;12(8):e0184093.
   PubMed Web of Science ®Google Scholar
• Wu S, Yin R, Ernest R, et al. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res. 2009;84(1):119–126.
   PubMed Web of Science ®Google Scholar
• Shi X, Zhang B, Chu Z, et al. Wogonin inhibits cardiac hypertrophy by activating Nrf-2-Mediated antioxidant responses. Cardiovasc Ther. 2021;2021:9995342.
   PubMed Web of Science ®Google Scholar
• Nguyen TTT, Ishida CT, Shang E, et al. Activation of LXR receptors and inhibition of TRAP1 causes synthetic lethality in solid tumors. Cancers (Basel). 2019;11(6):788.
   Web of Science ®Google Scholar
• Boureima Oumarou D, Ji H, Xu J, et al. Involvement of microRNA-23b-5p in the promotion of cardiac hypertrophy and dysfunction via the HMGB2 signaling pathway. Biomed Pharmacothe. 2019;116:108977.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fan X, Yang H. Long non-coding RNA FTX ameliorates hydrogen peroxide-induced cardiomyocyte injury by regulating the miR-150/KLF13 axis. Open life sciences. 2020;15(1):1000–1012.
   PubMed Web of Science ®Google Scholar
• Li K, Lin Y, Li C. MiR-338-5p ameliorates pathological cardiac hypertrophy by targeting CAMKIIδ. Arch Pharm Res. 2019;42(12):1071–1080.
   PubMed Web of Science ®Google Scholar
• Frey N, Katus HA, Olson EN, et al. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580–1589.
   Google Scholar
• Sriramula S, Francis J, Sovari AA. Tumor necrosis factor - Alpha is essential for Angiotensin II-Induced ventricular remodeling: role for oxidative stress. PLoS One. 2015;10(9):e0138372.
   PubMed Web of Science ®Google Scholar
• Xu E, Zhang J, Zhang M, et al. RNA-binding protein RBM24 regulates p63 expression via mRNA stability. Mol Cancer Res. 2014;12(3):359–369.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jun Cho S, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci U S A. 2010;107(21):9614–9619.
   PubMed Web of Science ®Google Scholar
• Cho SJ, Zhang J, Chen X. RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res. 2010;38(7):2256–2267.
   PubMed Web of Science ®Google Scholar
• Alvarez-Dominguez JR, Zhang X, Hu W. Widespread and dynamic translational control of red blood cell development. Blood. 2017;129:619–629.
   Google Scholar
• Warzecha CC, Sato TK, Nabet B, et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009;33(5):591–601.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Hidaka K, Jin D, et al. RNA-binding proteins Rbm38 and Rbm24 regulate myogenic differentiation via p21-dependent and -independent regulatory pathways. Genes Cells. 2009;14(11):1241–1252.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu E, Ren C, et al. Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors. Proc Natl Acad Sci U S A. 2014;111(52):18637–18642.
   PubMed Web of Science ®Google Scholar
• Léveillé N, Elkon R, Davalos V, et al. Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nat Commun. 2011;2(1):513.
   PubMedGoogle Scholar
• She X, Lin Y, Liang R, et al. RNA-Binding Motif protein 38 as a potential biomarker and therapeutic target in cancer. Onco Targets Ther. 2020;13:13225–13236.
   PubMed Web of Science ®Google Scholar
• Cannon MV, Silljé HHW, Sijbesma JWA, et al. LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. Diabetologia. 2016;59(3):634–643.
   PubMed Web of Science ®Google Scholar
• Kuipers I, Li J, Vreeswijk-Baudoin I, et al. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail. 2010;12(10):1042–1050.
   PubMed Web of Science ®Google Scholar
• Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature. 2007;445(7124):219–223.
   PubMed Web of Science ®Google Scholar
• Cannon MV, Yu H, Candido WM, et al. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Eur J Heart Fail. 2015;17(3):273–282.
   PubMed Web of Science ®Google Scholar
• Cannon MV, van Gilst WH, de Boer RA. Emerging role of liver X receptors in cardiac pathophysiology and heart failure. Basic Res Cardiol. 2016;111(1):3.
   PubMed Web of Science ®Google Scholar
• Cannon MV, Silljé HH, Sijbesma JW, et al. Cardiac LXR α protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med. 2015;7(9):1229–1243.
   PubMed Web of Science ®Google Scholar
• Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc. 2019;8(12):e012673.
   PubMed Web of Science ®Google Scholar
• Giudice J, Cooper TA. RNA-binding proteins in heart development. Adv Exp Med Biol. 2014;825:389–429.
   PubMed Web of Science ®Google Scholar